Authors : Jasper Caparic; Lovely Crissa Mae Cargo; Cyrell Jane Gaston; Dessa Mae C. Lancion; Gecelene C. Estorico

Volume/Issue : Volume 9 - 2024, Issue 11 - November

Google Scholar : https://tinyurl.com/22kz2jj7

Scribd : https://tinyurl.com/46by8ytw

DOI : https://doi.org/10.5281/zenodo.14287644

Abstract : Chronic Hepatitis B be easily managed through antiviral therapies that significantly reduce viral load, thereby decreasing liver inflammation and slowing the progression of liver fibrosis and cirrhosis of a patient. However, their clinical efficacy and safety has yet to be thoroughly determined. Different treatment varies widely in terms of effectiveness and safety concerns, with each treatment’s extremity. Moreover, they often elicit different responses across patients due to factors influencing their efficiency such as their age, liver health and immune health status. In this systematic review, we will investigate the different oral antiviral therapies for achieving sustained viral suppression in adults with their efficacy and their corresponding outcomes. 12 various studies were collected using relevant databases like PubMed, Web of Science and Scorpus across Asia and had been analyzed and reviewed. This study evaluated four antiviral drugs including entecavir (ETV), tenofovir (TDF), lamivudine (3TC), and telbivudine (LdT) with treatment variations varied from 1 to 5 years aiming to assess the patients’ varying degrees of efficacy such as ALT levels and HBeAg status after receiving the treatment. When comparing the therapeutic medicines, Tenofovir was determined to be effective in reducing viral load (3.4 ± 1.4 log10 IU/mL) and ALT levels (46.9 ± 49.8 U/L) in patients with mild to moderate liver inflammation. On the other hand, lamivudine exhibits moderate ALT levels (74.4± 94.7 U/L) and viral loads (6.88 ± 0.62 log10 IU/mL), making this treatment suitable for those experiencing moderate inflammation and requiring effective viral suppression and telbivudine displayed a notable ability to induce both HBeAg seroconversion of 46.4% and HBsAg loss of 31.1%. Overall, Entecavir consistently exhibited superior performance with 99. 4% in viral suppression and 94.5% liver function improvement.

Keywords : Viral Suppression, Hbeag-Positive, Hbeag- Negative, Seroconversion, Amino Transaminase Level (ALT)

References :

1. Buti, M. (MD), Riveiro-Barciela, M. (MD,PhD), & Esteban, R. (MD) (2021). Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy. Clinics in Liver Disease. 1089-3261/21. https://doi.org/10.1016/j.cld.2021.06.003
2. Cho, J., Sohn, W., Sinn, D., Gwak, G., Paik, Y., Choi, M. S., Koh, K. C., Paik, S. W., Yoo, B. C., & Lee, J. H. (2016). Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. The Korean Journal of Internal Medicine, 32(4), 636–646. https://doi.org/10.3904/kjim.2016.096
3. Kayaaslan B., & Guner R. (2017) Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol 2017; 9(5): 227-241  https://dx.doi.org/10.4254/wjh.v9.i5.227
4. Liang, X., Cheng, J., Sun, Y., Chen, X., Li, T., Wang, H., Jiang, J., Chen, X., Long, H., Tang, H., Yu, Y., Sheng, J., Chen, S., Niu, J., Ren, H., Shi, J., Dou, X., Wan, M., Jiang, J., . . . Hou, J. (2014). Randomized, three‐arm study to optimize lamivudine efficacy in hepatitis B e antigen‐positive chronic hepatitis B patients. Journal of Gastroenterology and Hepatology, 30(4), 748–755. https://doi.org/10.1111/jgh.12835
5. Liang, X., Xie, Q., Shang, J., Tang, H., Xu, M., Meng, Q., Zhang, J., Gao, P., Sheng, J., Wang, H., Jia, J., Wang, G., Wu, S., Ping, J., & Hou, J. (2021). Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough? Journal of Gastroenterology and Hepatology, 37(3), 471–479. https://doi.org/10.1111/jgh.15757
6. Lim, Y., Lee, Y. S., Gwak, G., Byun, K. S., Kim, Y. J., Choi, J., An, J., Lee, H. C., Yoo, B. C., & Kwon, S. Y. (2017). Monotherapy with tenofovir disoproxil fumarate for multiple drug‐resistant chronic hepatitis B: 3‐year trial. Hepatology, 66(3), 772–783. https://doi.org/10.1002/hep.29187
7. Sriprayoon, T., Mahidol, C., Ungtrakul, T., Chun‐on, P., Soonklang, K., Pongpun, W., Laohapand, C., Dechma, J., Pothijaroen, C., Auewarakul, C., & Tanwandee, T. (2016). Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial. Hepatology Research, 47(3). https://doi.org/10.1111/hepr.12743
8. Srivastava,  M., Singh, N., Dixit, V. K., Nath, G., & Jain, A. K. (2016d). Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study. The Indian Journal of Medical Research, 144(3), 424. https://doi.org/10.4103/0971-5916.198674
9. Sun, J., Xie, Q., Tan, D., Ning, Q., Niu, J., Bai, X., Fan, R., Chen, S., Cheng, J., Yu, Y., Wang, H., Xu, M., Shi, G., Wan, M., Chen, X., Tang, H., Sheng, J., Dou, X., Shi, J., . . . Hou, J. (2014). The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: A randomized, controlled study. Hepatology, 59(4), 1283–1292. https://doi.org/10.1002/hep.26885
10. Tsai, M., Chen, C., Hung, C., Lee, C., Chiu, K., Wang, J., Lu, S., Tseng, P., Chang, K., Yen, Y., & Hu, T. (2013). A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match–control study. Clinical Microbiology and Infection, 20(2), O90–O100. https://doi.org/10.1111/1469-0691.12220
11. Wang, C., Lin, C., Hsieh, T., Tseng, K., Peng, C., Su, T., Yang, S., Hsu, Y., Chen, T., & Kao, J. (2015). Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. Hepatology International, 10(2), 294–301. https://doi.org/10.1007/s12072-015-9662-9
12. Xie, Y., Ma, H., Feng, B., & Wei, L. (2017). Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients. Chinese Medical Journal, 130(18), 2190–2197. https://doi.org/10.4103/0366-6999.213969
13. Yue-Meng, W., Li, Y., Wu, H., Yang, J., Xu, Y., Yang, L., & Yang, J. (2016b). Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis. Clinical and Experimental Medicine, 17(2), 233–241. https://doi.org/10.1007/s10238-016-0420-7
14. Zhou, J., Liu, Y., Lian, J., Pan, L., Yang, J., & Huang, J. (2017). Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues. Chinese Medical Journal, 130(8), 914–919. https://doi.org/10.4103/0366-6999.204107